Cable One, Inc. CABO 深 滬
已收盤 08-01 16:00:00 美东时间
136.77
+8.790
+6.87%
華盛通- 最 高141.975
- 今 開138.80
- 成交量 41.71万股
- 最 低 131.66
- 昨 收 127.98
- 總市值 7.70亿
- 52周最高 431.095
- 市盈率 靜 53.10
- 換手率 7.41%
- 52周最低 117.54
- 委 比 50.00%
- 總股本 562.78万
- 歷史最高 2278.75
- 量 比 1.81
- 振 幅 8.06%
- 歷史最低 117.54
- 每 手 1
- 風險率 81.33%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Wells Fargo Maintains Underweight on Cable One, Lowers Price Target to $120
Wells Fargo analyst Steven Cahall maintains Cable One (NYSE:CABO) with a Underweight and lowers the price target from $210 to $120.
08-01 22:39
EchoStar Earnings Preview
EchoStar (NASDAQ:SATS) is gearing up to announce its quarterly earnings on Frid...
08-01 01:02
Earnings Scheduled For July 31, 2025
Companies Reporting Before The Bell • Vanguard Extended Duration Treasury ETF (...
07-31 16:32
Earnings Preview: Comcast
Comcast (NASDAQ:CMCSA) will release its quarterly earnings report on Thursday, ...
07-30 22:02
Cabot Corporation Launches New LITX® 95F Conductive Carbon Engineered for Energy Storage Systems
Cabot Corporation launches LITX 95F, a conductive carbon additive for lithium-ion batteries in energy storage systems (ESS), enhancing conductivity, cycle life, and processability for residential, commercial, and industrial applications. The product addresses the growing demand for reliable energy storage amid the shift to renewable energy and grid flexibility, offering improved cycle life, energy density, and cost efficiency. Jeff Zhu, EVP and P...
07-29 13:00
Exelixis Announces EU Approval Of CABOMETYX As First Systemic Therapy For Previously Treated Neuroendocrine Tumors
– Approval is based on the phase 3 CABINET pivotal trial, in which CABOMETYX demonstrated a statistically significant and clinically meaningful improvement in progression-free survival versus placebo –– CABOMETYX is the
07-25 05:05
Cabot Corporation Board Declares Dividend
Cabot Corporation declared a quarterly dividend of $0.45 per share on all outstanding shares of its common stock. The dividend will be paid on September 11, 2025, to stockholders of record as of August 29, 2025. Cabot Corporation is a global leader in specialty chemicals and performance materials, providing products like reinforcing carbons, battery materials, and aerogels.
07-11 21:00
Cabot Corporation to Announce Third Quarter 2025 Operating Results
<p>Cabot Corporation (NYSE: CBT) announced it will release third quarter fiscal 2025 operating results on August 4, 2025, after market close. A conference call and live webcast to discuss the results will begin at 8:00 am ET on August 5, 2025. The call will be accessible via webcast on Cabot’s website at https://cabotog.gcs-web.com/, with an archived version available afterward. Cabot, headquartered in Boston, is a global leader in specialty chem...
07-08 20:41
Exelixis' Partner Ipsen Received A Positive Opinion From The European Medicine Agency's Committee For Medicinal Products For Human Use For Cabometyx (Cabozantinib) For Adult Patients With Previously Treated Advanced Neuroendocrine Tumors
A regulatory decision by the European Medicines Agency is anticipated in 2025.In March 2025, the U.S. Food and Drug Administration approved CABOMETYX in this setting.
06-20 18:56
Cabaletta Bio Announces Proposed Public Offering of Securities
Cabaletta Bio, a clinical-stage biotechnology company specializing in targeted cell therapies for autoimmune diseases, has initiated an underwritten public offering of its common stock and warrants, with underwriters having a 30-day option to purchase additional shares. The offering is subject to market conditions and is expected to close on June 12, 2025. Jefferies, TD Cowen, and Cantor are acting as joint book-running managers. The company aims...
06-11 10:15
